MedTrace Logo

SCREEN-HFI (SCReening Evaluation of the Evolution of New Heart Failure Intervention Study)

NCT00604006 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-06-04

No results posted yet for this study

Summary

Individuals who were a part of the investigators Screen-HF study (NCT00400257) whose BNP level are in the top quintile will be offered participation in this study. Participants will be randomised to receive either spironolactone or placebo for three years. Participants will then be monitored for indications of heart failure. It is anticipated that the medication will reduce the development of heart failure in this group.

Conditions

Interventions

DRUG

Spironolactone

25 mg tablets (placed in capsules for blinding) once daily.

DRUG

Placebo

Placebo (lactose in capsules for blinding) once daily

Sponsors & Collaborators

  • National Heart Foundation, Australia

    collaborator OTHER

  • Monash University

    lead OTHER

Principal Investigators

  • Henry Krum, MBBS FRACP PhD · Monash University / Alfred Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-08-31
Completion
2015-01-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00604006 on ClinicalTrials.gov